medigraphic.com
Boletín Médico del Hospital Infantil de México

2008, Number 2

<< Back Next >>

Bol Med Hosp Infant Mex 2008; 65 (2)

Metabolic syndrome in cancer patients under chemotherapy treatment

Herrera-Silva JC, Treviño-Moore A, López-Beltrán AL

Language: Spanish
References: 22
Page: 110-120
PDF size: 161.79 Kb.


ABSTRACT

Introduction. Metabolic syndrome is one of the main health problem worldwide including cancer patients. Objectives. To know and to compare the prevalence of the metabolic syndrome in children with different neoplasms over chemotherapy treatment.
Methods. Through prospective, longitudinal, comparative and analytical study, anthropometric, clinical and blood measurements were carried out in a group of pediatrics patients with cancer.
Results. Fifty-eight patients participated. The global prevalence of the syndrome was 32.75 at the beginning, and 79.31% at the end. The 3 measurements were different for syndrome indicators as well as the number of positive patients (P ‹0.05). Blood pressure, height and weight were moderately associated with waist and hip perimeters.
Conclusions. The metabolic syndrome prevalence in pediatric cancer patients is very high, with no difference due to cancer type.


REFERENCES

  1. Lozano BG. Mesa redonda: El tejido adiposo como glándula endocrina. Obesidad y síndrome metabólico. Síndrome metabólico en la infancia. Bol Pediatr. 2006; 46: 292-9.

  2. National Cholesterol Education Panel. Report of the expert panel on blood cholesterol levels in children adolescents. Bethesda, Md: National Institutes of Health, NIH publication No. 91-2732; 1991.

  3. Fruhbeck G, Gómez-Ambrosi J, Muruzabal FJ, Burell MA. The adypocite: a model for integration of endocrine and metabolic signaling in energy metabolism regulation. Am J Physiol. 2001; 280: E827-47.

  4. Parsons SK, Skapek SX, Neufeld EJ, Kuhlman C, Young ML, Donnelly M, et al. Asparginase-associated lipid abnormalities in children with acute lymphoblastic leukemia. Blood. 1997; 89: 1886-95.

  5. Gleeson HK, Shalet SM. The impact of cancer therapy on the endocrine system in survivors of childhood brain tumors. Endocr Relat Cancer. 2004; 11: 589-602.

  6. Warner JT, Evans WD, Webb DKH, Gregory JW. Pitfalls in the assessment of body composition in survivors of acute lymphoblastic leukaemia. Arch Dis Child. 2004; 89: 64-8.

  7. Warner JT, Bell W, Webb DKH, Gregory JW. Relationship between cardiopulmonary response to exercise and adiposity in survivors of childhood malignancy. Arch Dis Child. 1997; 76: 298-303.

  8. Reilly JJ, Nelly A, Ness P, Dorosty RA, Wallace HB, Gibson BES. Premature adiposity rebound in children treated for acute lymphoblastic leukemia. J Clin Endocrinol Metab. 2001; 86: 2775-8.

  9. Hijiya N, Panetta JC, Zhou Y, Kyzer EP, Howard SC, Jeha S, et al. Body mass index does not influence pharmacokinetics or outcome of treatment in children with acute lymphoblastic leukemia. Blood. 2006; 106: 1691-5.

  10. Yeung JSC, Cua CA, Vassilopoulou-Sellin R, Gagel RF. The endocrine effects of nonhormonal antineoplastic therapy. Endocr Rev. 1998; 19: 144-72.

  11. Sonnenberg GE, Krakower GR, Kissebah AH. A novel pathway to the manifestations of metabolic syndrome. Obes Res. 2004; 12: 180-6.

  12. Dunstan DW, Zimmet PZ, Welborn TA, de Courten MP, Cameron AJ, Sicree RA, et al. The rising prevalence of diabetes and impaired glucose tolerante. The Australian diabetes, Obesity and life-style study. Diabet Care. 2002; 25: 829-34.

  13. Posadas RC. Obesidad y el síndrome metabólico en niños y adolescentes. Rev Endocrinol Nutr. 2005; 13: S45-6.

  14. Cook S, Diezman M, Avinger P. Prevalence of metabolic syndrome phenotype in adolescents. Finding from the third National Health and Nutrition Examination Survey 1988-1994. Arch Pediatr Adolesc Med. 2003; 157: 821-7.

  15. Wisse BE. The inflammatory syndrome: The role adipose tissue cytokines in metabolic disorders linked to obesity. J Am Soc Nephrol. 2004; 15: 2792-800.

  16. Van Donge-Melman JEWM, Hokken-Koelega ACS, Halen D, De Gorott A, Tromp CG, Egeler RM. Obesity after treatment for acute lymphoblastic leukemia in childhood. Pediatr Res. 1995; 38: 86-90.

  17. Didi M, Didecck E, Davies HA, Ogiluy-Stuart AL, Wales JKH, Shalet SM. High incident of obesity in young adults after treatment of acute lymphoblastic leukemia in childhood. J Pediatr. 1995; 127: 63-7.

  18. Gotthelf SJ, Jubany LL. Prevalencia de factores de riesgo asociados al síndrome metabólico en niños y adolescentes obesos de la ciudad de Salta 2004. Bethesta Md: National Institute of Health. NIH Publication Nº 2-5215. Sep.; 2004.

  19. Cruz ML, Shaibi GQ, Weigensberg MJ, Spruijt-Metz D, Ball GDC, Goran MI. Chronic disease risk and implications for treatment and prevention beyond boys weight modification. Ann Rev Nutr. 2005; 25: 435-68.

  20. Grundy SM. Metabolic syndrome. Connecting and reconciling cardiovascular and diabetes world. J Am Coll Cardiol. 2006; 47: 1093-100.

  21. International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome. Pan Am J Health. 2005; 18: 451-4.

  22. Brú A, Albertos S, Subiza JL, García-Asenjo JL, Brú I. The universal dynamics of tumor growth. Byophys J. 2003; 85: 2948-61.




2020     |     www.medigraphic.com